NCT07046819View on ClinicalTrials.gov

Tirzepatide in MetALD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions
Metabolic Alcohol-associated Liver DiseaseAlcohol Use Disorder
Interventions
DRUG

Tirzepatide

A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.

OTHER

Placebo

A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH